Health Trials

About this trial

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.

Eligibility criteria

Qualifiers

Patients ≥ 18 years of age

Confirmed histologic diagnosis of metastatic TNBC

1 site amenable cryoablation of at least 1.5 cm in size as determined by an Interventional Radiologist. Eligible cryoablation sites include (but not limited to) soft tissue, liver, lung, and bone as determined by an Interventional Radiologist to be safest and most feasible.

Physically fit (clinically eligible) to undergo cryoablation as per usual clinical practice

Disqualifiers

Patient not eligible for PD-1 inhibitor per the patient's medical oncologist

No disease amenable for cryoablation

Pembrolizumab therapy not planned as part of standard of care

Trial design

Treatments tested in this trial

  • Pembrolizumab
  • Cryoablation

Treatment groups

30 Participants
are divided into 2 treatment groups

Locations

7
Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities)07920, Basking RidgeNew Jersey, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities)07748, MiddletownNew Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)07645, MontvaleNew Jersey, United States
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities )11725, CommackNew York, United States

Sponsors and collaborators

Memorial Sloan Kettering Cancer Center

Lead sponsor

Source ClinicalTrials.gov